REGENERATIVE MEDICINE – Page 46 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2019-08-28

Mesenchymal stem cells in allergic diseases: Current status

Allergic diseases have become a global health problem and the most prevalent allergic disorders include allergic asthma, allergic skin diseases, allergic rhinitis, and allergic conjunctivitis. In the therapy of allergic diseases, corticosteroids, antihistamines, antileukotrienes and β2 adrenergic receptor agonists temporarily inhibit inflammation mediators and immune cells. However, long-term treatment causes various adverse effects. Drug resistance and intolerance

No Comments InAUTOIMMUNE DISEASES

PIER MARIA FORNASARI
2019-08-28

Novel method identifies the right individual exosomes

There is a growing demand for diagnostic markers for early disease detection and prognosis. Exosomes are potential biomarkers for cancer progression and neurodegenerative disease but it can be difficult to identify what tissue a specific exosome comes from. Researchers at Uppsala University and spin-off company Vesicode AB have solved the problem by developing a method

No Comments InEXOSOMES

PIER MARIA FORNASARI
2019-08-28

Merging organoid and organ-on-a-chip technology to generate complex multi-layer tissue models in a human Retina-on-a-Chip platform

The development of a retina-on-a-chip, which combines living human cells with an artificial tissue-like system, has been described today in the open-access journal eLife. This cutting-edge tool may provide a useful alternative to existing models for studying eye disease and allow scientists to test the effects of drugs on the retina more efficiently. Many diseases that

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2019-08-27

DiscGenics Receives FDA Fast Track Designation for Cell Therapy for Disc Degeneration

DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational cell therapy, IDCT, currently being evaluated in regulator-allowed clinical trials

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2019-08-27

The Alliance for Regenerative Medicine Releases Statement of Principles on Genome Editing

The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today released a Therapeutic Developers’ Statement of Principles, setting forth a bioethical framework for the use of gene editing in therapeutic applications. The statement, developed by ARM’s Gene Editing Task Force and signed by

No Comments InGENOME

PIER MARIA FORNASARI
2019-08-27

Adoptive cell therapy using engineered natural killer cells

The generation of autologous T cells expressing a chimeric antigen receptor (CAR) have revolutionized the field of adoptive cellular therapy. CAR-T cells directed against CD19 have resulted in remarkable clinical responses in patients affected by B-lymphoid malignancies. However, the production of allogeneic CAR-T cells products remains expensive and clinically challenging. Moreover, the toxicity profile of

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2019-08-27

Promising Gene Replacement Therapy for Niemann-Pick type A disease Moves Forward At Ohio State

Research led by Dr. Krystof Bankiewicz, who recently joined The Ohio State University College of Medicine, shows that gene replacement therapy for Niemann-Pick type A disease is safe for use in nonhuman primates and has therapeutic effects in mice. These research findings are published online in the journal Science Translational Medicine. Prior to joining Ohio State as a professor

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2019-08-27

MAPPING EYE DISEASE

Researchers have created the world’s most detailed atlas of the genetic code of the human retina, and it could help treat and prevent blindness The transcriptome of human neural retina at a single‐cell level defines the gene expression profile in major cell types in the neural retina and can be used as a benchmark to

No Comments InGENOME

PIER MARIA FORNASARI
2019-08-26

Ability to ‘bridge the gap’ key to making UK a biopharma powerhouse

The UK’s departure from the European Union looks likely to dent many sectors at least in the short to medium term, but the biopharmaceutical industry is one that might just continue to shine, however damaging the exit from the trade bloc proves to be. The quality of innovation coming out of labs, with 25 of

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2019-08-26

Organ-on-e-chip Biosensor Shrink Wraps Heart Cells

Researchers at Carnegie Mellon University (CMU) and Nanyang Technological University (NTU) in Singapore have developed an organ-on-an-electronic-chip biosensor technology that can measure the electrophysiology of heart cell structures in three dimensions. The biosensor array essentially self-rolls around elongated spheroids of stem cell-derived cardiac cells—similar to how a “slap bracelet” wraps around a wrist—giving researchers the

No Comments InORGAN ON CHIP

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Category REGENERATIVE MEDICINE

Mesenchymal stem cells in allergic diseases: Current status

Novel method identifies the right individual exosomes

Merging organoid and organ-on-a-chip technology to generate complex multi-layer tissue models in a human Retina-on-a-Chip platform

DiscGenics Receives FDA Fast Track Designation for Cell Therapy for Disc Degeneration

The Alliance for Regenerative Medicine Releases Statement of Principles on Genome Editing

Adoptive cell therapy using engineered natural killer cells

Promising Gene Replacement Therapy for Niemann-Pick type A disease Moves Forward At Ohio State

MAPPING EYE DISEASE

Ability to ‘bridge the gap’ key to making UK a biopharma powerhouse

Organ-on-e-chip Biosensor Shrink Wraps Heart Cells